Levels of IRB Review: Convened, Expedited and Limited

Part of Human Subjects Protection for Clinical Research Staff: What Counts as Human Subjects Research.

About 6 minutes. Free, in your language, no account needed.

Why this matters

Not every study gets the same kind of IRB review, and the type of review changes how long you wait, who reads your submission and what happens after approval. Knowing the three levels helps you set honest timelines with the PI and the sponsor, and helps you understand an approval letter when it arrives.

This lesson uses the US rules (HHS 45 CFR 46 and FDA 21 CFR 56) as the worked example. Under ICH E6(R3), the international baseline, the IRB/IEC reviews the trial and conducts continuing review at intervals appropriate to the degree of risk. Outside the United States, follow your national law and ethics committee requirements.

Convened review: the full committee

Research that is not reviewed by an expedited procedure is reviewed at convened meetings of the IRB. A majority of members must be present, including at least one member whose primary concerns are in nonscientific areas, and approval requires a majority of those present (45 CFR 46.108(b); 21 CFR 56.108(c)).

This is the review with the most people looking at the protocol. It also means your submission may have to wait for a scheduled meeting.

Expedited review: a smaller group, not a lower standard

Under 45 CFR 46.110 and 21 CFR 56.110, an IRB may use expedited review in three situations:

Under expedited review, the IRB chair or experienced reviewers designated by the chair may exercise the IRB's authority, with one important exception: they may not disapprove the research. Disapproval requires non-expedited review, meaning a convened meeting.

Expedited does not mean casual. It means a smaller group can approve research that fits the list. If the reviewer determines the study involves more than minimal risk, the list does not apply.

Limited IRB review: a condition of certain exemptions

In the United States, limited IRB review is a 2018 Requirements condition attached to certain exemptions: (d)(2)(iii), (d)(3)(i)(C), (d)(7) and (d)(8) of 45 CFR 46.104. The IRB reviews the study and may approve it, require modifications or disapprove it (46.109(a)). What it checks depends on the category: privacy and confidentiality protections (46.111(a)(7)) for (d)(2)(iii), (d)(3)(i)(C) and (d)(8), the broad consent determinations (46.111(a)(8)) for (d)(7), and for (d)(8) also that the research is within the scope of the broad consent.

It is limited in scope, but it is still an actual IRB decision. The key point for you is that "exempt" does not always mean "no IRB involvement." Some exempt research needs limited review first.

Continuing review and its exceptions

In the United States, under the 2018 Common Rule, research that requires review by the convened IRB gets continuing review at intervals appropriate to the degree of risk, not less than once per year, and the IRB has authority to observe or have a third party observe the consent process and the research (46.109(e), (g)). Continuing review is not required (unless the IRB determines otherwise) for:

These exceptions are 2018 Requirements features. They do not apply to studies still under the pre-2018 Requirements, and they do not apply under FDA's rule, which requires continuing review of the research it covers at least once per year (21 CFR 56.109(f)). An FDA-regulated trial that was eligible for expedited review still gets annual continuing review. If you are unsure which applies to your study, ask the IRB office. Do not assume a study is free of continuing review: check the approval letter and ask.

Putting the levels side by side

In practice

A coordinator is planning the timeline for a new interventional study. The PI says, "Can we get expedited review so we can start next week?" The coordinator pulls the protocol and checks: it assigns participants to an investigational drug, so it is not a listed expedited category. She tells the PI that she expects it to need a convened meeting, and she asks the IRB office to confirm. She builds the start-up plan around it and warns the sponsor contact early.

What this looks like when it goes wrong

A site has an approved minimal-risk study. Months later the PI adds an extra procedure and the coordinator submits the change as a "minor amendment" for expedited review, with no description of how risk is affected. The reviewer, seeing that the new procedure may increase risk, escalates it. The site loses weeks and realizes it had scheduled participants for the new procedure before approval arrived.

A label chosen for speed backfired: the review level follows the facts of the study, not the preference of the team.

Key takeaways